Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ:EGRX opened at $1.49 on Friday. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.37. The company’s 50-day moving average price is $1.05 and its two-hundred day moving average price is $1.32.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in Eagle Pharmaceuticals in the 3rd quarter valued at $96,000. DGS Capital Management LLC boosted its stake in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after purchasing an additional 22,239 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Eagle Pharmaceuticals in the third quarter valued at approximately $453,000. Finally, RBF Capital LLC boosted its stake in Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares during the last quarter. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.